山东步长制药股份有限公司 关于为公司控股子公司提供担保的公告 证券代码：603858 证券简称：步长制药 公告编号：2025-228 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 北京博源润步医药研发有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 2,200 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 0 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | ☑否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 231,830.79 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 22.69 | | 特别风险提示（如有请勾 ...

Core Viewpoint - The news highlights the significant advancements in technology innovation and development in Heze City during the "14th Five-Year Plan" period, emphasizing the integration of technological and industrial innovation to support high-quality economic growth [1][4]. Group 1: Major Changes in Technology Management - The establishment of the Heze Municipal Science and Technology Committee enhances the unified leadership of technology work, coordinating major strategic tasks and policies across the city [3]. Group 2: Investment and Innovation Capacity - R&D expenditure has significantly increased, with a growth rate leading the province for two consecutive years, reaching 1.47% of GDP, an increase of 0.72 percentage points since 2020 [4]. - The innovation platform system has improved, with 4 provincial key laboratories and over 400 municipal key laboratories established, along with 3 provincial and 200 municipal technology innovation centers [4]. - The high-level talent pool has expanded, with 7 overseas experts included in national talent programs and over 30 leading industry talents recruited [4]. Group 3: Support for R&D Projects - Over 2,000 national and provincial technology plan projects have been implemented, securing nearly 600 million yuan in project funding [5]. - The city has organized annual technology innovation breakthrough projects, with several approved as major provincial projects [5]. Group 4: Growth of High-Tech Industries - By the end of 2024, high-tech industries are expected to account for over 42% of the total industrial output, an increase of 4.27 percentage points since 2020 [6]. - The number of high-tech enterprises is projected to exceed 600, doubling since the beginning of the "14th Five-Year Plan," while the number of technology-based SMEs has increased 4.3 times since 2020 [6]. - Significant technological achievements have been recognized, with two projects nominated for provincial science and technology awards, marking a major breakthrough for Heze [6]. Group 5: Optimizing the Innovation Environment - The city has intensified efforts to mobilize and guide technology innovation, holding annual technology conferences and organizing various technology activities to foster a strong innovation atmosphere [7]. - Policies supporting small and micro enterprises have been implemented, with over 60 million yuan allocated for high-tech enterprise upgrades and more than 1,000 companies receiving R&D subsidies [8]. - The financial support for technology transfer has been enhanced, with over 2 billion yuan in loans for technology transfer projects [8]. Group 6: Development in Agriculture and Social Technology - The city has established various agricultural technology parks and has achieved significant advancements in agricultural innovation, including the approval of new wheat varieties [10]. - Major biomedical projects have been successfully implemented, contributing to health innovation [10]. - Efforts in ecological and environmental technology have been made, promoting green and low-carbon enterprises [10]. Group 7: Domestic and International Technology Cooperation - Numerous technology cooperation activities have been organized, establishing stable partnerships with over 120 universities and research institutions [11]. - Several technology cooperation bases and innovation centers have been established, facilitating collaborative projects and technology transfer [12]. Group 8: Future Directions for Technology Innovation - The city aims to enhance strategic technology capabilities, focusing on key technology breakthroughs and accelerating technology transfer to overcome industrial bottlenecks [13]. - There is a commitment to strengthen the role of enterprises in technological innovation and to cultivate a robust ecosystem for high-tech enterprises [13]. - Continuous reforms in the technology system will be pursued to stimulate innovation and entrepreneurship [14]. - The establishment of a first-class technology innovation ecosystem is a priority, focusing on service systems, financial environments, and intellectual property protection [14].

Group 1 - The company announced the completion of business registration changes for its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd. [1] - The changes include an updated business scope, which now encompasses traditional Chinese medicine extraction, medical research and development, and solar power technology services [1] - The registered capital of Yangling Buchang is 158 million RMB, and the company was established on August 31, 2010 [1] Group 2 - The company reported that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received approval from the Hebei Provincial Drug Administration for changes to its drug production license [3] - The changes include the addition of new production lines and workshops, specifically for soft capsule production and oral solution production lines [4][5] - The production license is valid until July 7, 2030, and the company is authorized to produce various forms of medications, including ointments, tablets, and oral solutions [4][5]

Core Insights - The flu positive rate in China has reached nearly 45%, indicating a significant rise in flu cases, with some provinces experiencing high epidemic levels [1] - Investors are closely monitoring the supply and sales of flu medications and vaccines from listed pharmaceutical companies, which are actively preparing to meet public health needs [1] Group 1: Drug and Vaccine Supply - Multiple listed companies have reported sufficient reserves of flu medications and vaccines, ensuring stable supply capabilities [2] - Renhe Pharmaceutical has initiated a priority supply mechanism for Oseltamivir, while Dajia Weikang has adjusted production capacity based on market demand [2] - The entire supply chain, including raw material suppliers like Rhine Bio, is collaborating to ensure a robust response to market needs [2] Group 2: Vaccine Development - Companies are focusing on flu vaccines as a key area for development, with several achieving significant progress by 2025 [3] - Zhejiang Tianyuan Biopharmaceutical's quadrivalent flu vaccine "Yufening" has been approved for sale, alongside its trivalent vaccine "Yuganning" [3] - Baike Bio has innovated with a freeze-dried nasal spray flu vaccine, which has been upgraded to a liquid form for easier administration [3] Group 3: Treatment Options - Companies are building a diverse matrix of flu medications to address various symptoms and treatment needs [5] - Zhongsheng Pharmaceutical is advancing the commercialization of Anladiwei tablets for treating uncomplicated influenza, while Jichuan Pharmaceutical is developing a novel flu treatment [5] - Oseltamivir remains a commonly used antiviral, with multiple companies like Renfu Pharmaceutical and Dajia Weikang actively involved in its production [5][6] Group 4: Symptomatic Relief - Several companies are providing symptomatic treatments for flu, including Lisheng Pharmaceutical's Acetaminophen and various products from Zhenbaodao for symptom relief [6] - Companies like Foci Pharmaceutical produce a range of cold and flu medications, ensuring comprehensive treatment options for patients [6]

Core Viewpoint - Company announced a change in the business scope of its wholly-owned subsidiary, Yangling Buchang Pharmaceutical Co., Ltd., to meet operational management needs [2] Group 1 - The fifth meeting of the fifth board of directors is scheduled for November 7, 2025, to review the proposal for the change in business scope [2] - Yangling Buchang has completed the industrial and commercial change registration procedures and obtained a new business license from the Yangling Demonstration Zone Market Supervision Administration [2]

关于全资子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603858 证券简称：步长制药 公告编号：2025-226 山东步长制药股份有限公司 经营范围：一般项目：中药提取物生产；医学研究和试验发展；非居住房 地产租赁；太阳能发电技术服务(除依法须经批准的项目外，凭营业执照依法自 主开展经营活动)。许可项目：药品生产；药品委托生产；药品进出口；药品批 发(依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目 1 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 11 月 7 日召开 第五届董事会第三十五次会议，审议通过了《关于全资子公司经营范围变更的议 案》，公司全资子公司杨凌步长制药有限公司（以下简称"杨凌步长"）因经营管 理之需要，拟对经营范围进行变更。具体内容详见公司 2025 年 11 月 8 日披露于 上海证券交易所网站（www.sse.com.cn）的《关于全资子公司经营范围变更的公 告》（公告编号：2025-209）。 近日，杨凌步长已完成工商变更 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-227 山东步长制药股份有限公司 关于全资子公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）近日获悉全资子公司保定 天浩制药有限公司（以下简称"保定天浩"）获得河北省药品监督管理局许可， 同意保定天浩《药品生产许可证》车间生产线、药品委托情况的变更，其他内容 不变，现将相关情况公告如下： 许可证编号：冀 20150057 一、药品生产许可证相关情况 企业名称：保定天浩制药有限公司 注册地址：河北省定兴县兴华东路 128 号 分类码：AhzBh 法定代表人：王益民 企业负责人：殷文忠 质量负责人：卢颖 生产地址和生产范围：河北省定兴县兴华东路 128 号：搽剂，软膏剂，片剂， 溶液剂（外用），乳膏剂，凝胶剂，灌肠剂，油剂，硬胶囊剂，颗粒剂，喷雾剂 （仅限注册申报使用）*** 山东省菏泽市中华西路 1668 号（山东步长神州制药有限公司）：集团内共 用中药提取、颗粒剂*** 1 山东步长制药股份 ...

Core Viewpoint - Company Baichang Pharmaceutical's subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received a renewed drug production license from the Hebei Provincial Drug Administration, allowing for changes in production lines and facilities, which is expected to positively impact the company's future operations [1] Group 1: License and Production Changes - The renewed drug production license includes the addition of a new workshop and production line located at 16 Bichang Road, Qindu District, Xianyang City, Shaanxi Province [1] - The new workshop is designated for soft capsule production, and the production line is for oral solution dosage forms, specifically Vitamin D drops [1] - The company has commissioned Shaanxi Baichang Pharmaceutical Co., Ltd. to produce Vitamin D drops with specific dosages, which currently do not have approval numbers [1] Group 2: Operational Impact - The changes in the drug production license are expected to optimize the company's production structure and maintain stable production capacity to meet market demand [1] - The license changes are anticipated to have a positive impact on the company's future operations [1]

Group 1 - Company provided a guarantee of 80 million RMB for its wholly-owned subsidiary, Shaanxi Buchang Pharmaceutical Co., Ltd., in a loan agreement with Huaxia Bank [2][7] - The board approved a total financing limit of up to 6.92 billion RMB for 2025, with specific guarantee limits for subsidiaries based on their debt ratios [3][12] - As of the announcement date, the total amount of guarantees provided by the company and its subsidiaries was 2.296 billion RMB, accounting for 22.48% of the company's audited net assets as of the end of 2024 [14] Group 2 - The company’s wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., signed a contract with Beijing Excellent Future International Pharmaceutical Technology Development Co., Ltd. for clinical trials of a new drug [17] - The total cost for the clinical trial is 60.338 million RMB, covering 480 cases, with provisions for adjustments based on the final sample size [19] - This contract is expected to enhance the company's drug research and development capabilities, potentially saving time and costs in clinical trials [34] Group 3 - The company’s subsidiary, Shaanxi Buchang, received approval for changes to its drug production license, allowing for the addition of a new production line for tablets [42] - The changes are anticipated to optimize production structure and maintain stable production capacity to meet market demand [43]

Policy Developments - The State Council, led by Li Qiang, held a meeting to advance the provincial coordination of basic medical insurance [2] Medical Device Approvals - Yuhanglong received two medical device registration certificates for diagnostic kits related to primary biliary cholangitis and idiopathic membranous nephropathy, enhancing its product line in liver and kidney disease diagnostics [4] - Hengrui Medicine announced the approval of clinical trial notifications for five drugs, including the humanized anti-PD-L1 monoclonal antibody Abedilizumab, with total R&D investments amounting to approximately 1.1 billion yuan [5] Capital Market Activities - Mindray Medical's chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan, having already purchased shares worth approximately 30 million yuan [7] - Huayu Pharmaceutical intends to establish a private equity fund focused on the biomedical sector, with an initial commitment of 150 million yuan from the company [8][9] Industry Milestones - The first brain-computer interface surgery in China was successfully completed, utilizing a device from Wuhan Zhonghua Brain-Machine Fusion Technology Co., with the procedure priced according to government regulations [11] Clinical Trials and Collaborations - Buchang Pharmaceutical's subsidiary signed a contract for clinical trials of a new product, with a total cost of approximately 60 million yuan, aimed at enhancing the company's drug development capabilities [12] - Jincheng Pharmaceutical terminated negotiations with Giskit Pharma B.V. regarding exclusive commercialization rights, with no financial impact expected [14]